$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000165731223000025 Filed on November 02, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$0.00	$0.00
YoY Change	-100.0%
Cost Of Revenue	$0.00
YoY Change	-100.0%
Gross Profit	$0.00
YoY Change	-100.0%
Gross Profit Margin
Selling, General & Admin	$14.97M	$13.35M
YoY Change	79.89%	152.42%
% of Gross Profit
Research & Development	$4.122M	$2.958M
YoY Change	-39.72%	-69.93%
% of Gross Profit
Depreciation & Amortization	$208.0K	$155.0K
YoY Change	37.75%	-1.27%
% of Gross Profit
Operating Expenses	$19.09M	$16.31M
YoY Change	25.94%	7.82%
Operating Profit	-$19.09M	-$16.31M
YoY Change	26.88%	7.82%
Interest Expense	$3.875M	$401.0K
YoY Change	-16.58%	245.69%
% of Operating Profit
Other Income/Expense, Net	$1.034M	$1.668M
YoY Change	29.9%	-466.59%
Pretax Income	-$14.19M	-$14.64M
YoY Change	36.09%	-6.03%
Income Tax	-$53.00K	$44.00K
% Of Pretax Income
Net Earnings	-$14.13M	-$14.69M
YoY Change	35.22%	-6.14%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.02
Diluted Earnings Per Share	-$0.02	-$0.02
COMMON SHARES
Basic Shares Outstanding	639.5M shares	635.9M shares
Diluted Shares Outstanding		638.2M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$271.8M	$257.4M
YoY Change	19.29%	11.08%
Cash & Equivalents	$271.8M	$257.4M
Short-Term Investments
Other Short-Term Assets	$3.365M	$6.319M
YoY Change	-0.68%	105.36%
Inventory	$0.00
Prepaid Expenses	$3.617M	$3.332M
Receivables	$0.00
Other Receivables
Total Short-Term Assets	$289.7M	$276.5M
YoY Change	19.22%	6.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.00K	$10.00K
YoY Change	-67.12%	-87.65%
Goodwill	$545.0K	$545.0K
YoY Change	0.0%	0.18%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M
YoY Change	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$18.42M	$15.94M
YoY Change	11.8%	-2.89%
TOTAL ASSETS
Total Short-Term Assets	$289.7M	$276.5M
Total Long-Term Assets	$18.42M	$15.94M
Total Assets	$308.1M	$292.5M
YoY Change	18.75%	6.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.492M	$823.0K
YoY Change	20.0%	-89.72%
Accrued Expenses	$3.585M	$7.397M
YoY Change	-73.93%	-67.81%
Deferred Revenue	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.692M	$9.012M
YoY Change	-54.32%	-71.95%
LONG-TERM LIABILITIES
Long-Term Debt	$48.37M	$19.91M
YoY Change	395.23%	298.1%
Other Long-Term Liabilities	$1.775M	$20.00K
YoY Change	765.85%	-91.07%
Total Long-Term Liabilities	$50.15M	$19.93M
YoY Change	402.85%	278.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.692M	$9.012M
Total Long-Term Liabilities	$50.15M	$19.93M
Total Liabilities	$58.84M	$28.94M
YoY Change	102.89%	-22.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$388.4M	-$374.1M
YoY Change	16.6%	16.04%
Common Stock	$42.77M	$41.75M
YoY Change	5.54%	6.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.517M	$746.0K
YoY Change	-2.07%	66.15%
Treasury Stock Shares
Shareholders Equity	$249.3M	$263.5M
YoY Change
Total Liabilities & Shareholders Equity	$308.1M	$292.5M
YoY Change	18.75%	6.4%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$14.13M	-$14.69M
YoY Change	35.22%	-6.14%
Depreciation, Depletion And Amortization	$208.0K	$155.0K
YoY Change	37.75%	-1.27%
Cash From Operating Activities	-$10.40M	-$12.73M
YoY Change	34.43%	-29.67%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	24.01M	48.00K
YoY Change	818.59%	-99.97%
NET CHANGE
Cash From Operating Activities	-10.40M	-12.73M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	24.01M	48.00K
Net Change In Cash	13.61M	-12.68M
YoY Change	-365.61%	-110.43%
FREE CASH FLOW
Cash From Operating Activities	-$10.40M	-$12.73M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$10.40M	-$12.73M
YoY Change	34.43%	-29.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	283000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	416000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1409000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9012000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19029000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19905000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9768000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	205000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	19925000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9973000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	28937000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	29002000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	651659630	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631338246	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	639520054	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	41753000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40526000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	601180000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	529187000	usd
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	746000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1549000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-374053000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333097000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	263533000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5290000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35381000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18256000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	16311000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	15128000	usd
	us-gaap	Operating Expenses OperatingExpenses	48475000	usd
	us-gaap	Operating Expenses OperatingExpenses	60701000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16311000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15128000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-48475000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-60701000	usd
CY2023Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	-309000	usd
CY2022Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	2127000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	70000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	8838000	usd
CY2023Q3	us-gaap	Investment Income Net InvestmentIncomeNet	3390000	usd
CY2022Q3	us-gaap	Investment Income Net InvestmentIncomeNet	779000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	9469000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	959000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	401000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	116000	usd
	us-gaap	Interest Expense InterestExpense	1434000	usd
	us-gaap	Interest Expense InterestExpense	291000	usd
CY2023Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-1012000	usd
CY2022Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-3245000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	660000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-6830000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1668000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-455000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39710000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	527000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	225000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14687000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-15647000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40237000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-58250000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631447851	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631447851	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	276749000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8807000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5074000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	273093000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	793000	usd
CY2022Q1	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	-118000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3747000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	126307000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-17766000	usd
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	606301054	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	292470000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259468000	usd
CY2023Q3	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	2958000	usd
CY2022Q3	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	9838000	usd
	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	13094000	usd
	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	42445000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13353000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58025000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638238749	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638238749	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	544134136	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	544134136	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	503751844	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	503751844	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16743000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56909000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1827000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4290000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14687000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	48000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5079000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	263533000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	usd
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	689000	usd
CY2022Q2	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	25000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3053000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	110880000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-15647000	usd
CY2022Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	371000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	900000	usd
CY2022Q3	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	182000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2815000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	237485000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40237000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-58250000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	660000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7105000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	103000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	67000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	84000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	94000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	14443000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9617000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	469000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	485000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	833000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-682000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	70000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	9113000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2260000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1014000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	351000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2087000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2042000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6355000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	722000	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-484000	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-141000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-954000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	138000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-979000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-123000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39820000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52124000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56909000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149797000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9582000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9996000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2382000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1952000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	371000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68857000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	138204000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	502000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2730000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29539000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	83321000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	257366000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231701000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1215000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	90000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1228000	usd
	us-gaap	Interest Paid Net InterestPaidNet	190000	usd
	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2023Q2	vrna	Payments For Application Fees PaymentsForApplicationFees	3200000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-374100000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company’s estimates.</span></div>
CY2023Q3	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	1486000	usd
CY2022Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	12314000	usd
CY2023Q3	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2245000	usd
CY2022Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	1364000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3666000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	74000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7397000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13752000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5079000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40237000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638239000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	544134000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19276496	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1320000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	240000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1050192	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19306304	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2824000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	80000	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	120000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21930304	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1400000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	60000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	160000	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	88000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23022304	shares
CY2023Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14687000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-15647000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631448000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631448000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	503752000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	503752000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	45900000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	45900000	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57700000	shares
CY2023Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	6900000	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1500000	usd
CY2023Q3	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	2100000	usd
CY2023Q2	vrna	Loss Contingency Accrual Reversal Of Research And Development Costs LossContingencyAccrualReversalOfResearchAndDevelopmentCosts	6300000	usd
	vrna	Loss Contingency Accrual Reversal Of Research And Development Costs LossContingencyAccrualReversalOfResearchAndDevelopmentCosts	1500000	usd
CY2023Q3	vrna	Operating Lease Square Feet Of Office Space OperatingLeaseSquareFeetOfOfficeSpace	31845	sqft
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2800000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
vrna-20230930_cal.xml	Edgar Link	unprocessable
0001657312-23-000025-index-headers.html	Edgar Link	pending
0001657312-23-000025-index.html	Edgar Link	pending
0001657312-23-000025.txt	Edgar Link	pending
0001657312-23-000025-xbrl.zip	Edgar Link	pending
exhibit311q323.htm	Edgar Link	pending
exhibit312q323.htm	Edgar Link	pending
exhibit321q323.htm	Edgar Link	pending
exhibit322q323.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20230930.htm	Edgar Link	pending
vrna-20230930.xsd	Edgar Link	pending
vrna-20230930_g1.jpg	Edgar Link	pending
vrna-20230930_def.xml	Edgar Link	unprocessable
vrna-20230930_lab.xml	Edgar Link	unprocessable
vrna-20230930_pre.xml	Edgar Link	unprocessable
vrna-20230930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2023 Q4 Form 10-Q Financial Statement

#000165731223000025 Filed on November 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2023 Q4 Form 10-Q Financial Statement

#000165731223000025 Filed on November 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna